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ABSTRACT
TITLE: A COMPARATIVE EVALUATION OF RADIOLOGIC AND
CLINICAL SCORING SYSTEMS IN EARLY PREDICTION OF
SEVERITY IN ACUTE PANCREATITIS
AUTHOR: DR. S. VIJAY RAJ M.S POST GRADUATE
KEYWORDS: Pancreatitis, Bisap, Glasgow, Ct Severity Index, Organ
Failure,
BACKGROUND: Demographic, clinical, and laboratory data of all
consecutive patients with a primary diagnosis of ACUTE
PANCREATITIS  during a one year period is prospectively  collected for
this study. A retrospective analysis of the abdominal CT data is
performed. CT severity index as well as two clinical scoring systems:
Glasgow criteria / IMRIE’S prognostic criteria and Bedside Index for
Severity in Acute pancreatitis (BISAP) were comparatively evaluated
with regard to their ability to predict the severity of acute pancreatitis on
admission (within 48 h of hospitalization).
First 50 patients attending the surgical emergency ward with
clinical features of Acute Pancreatitis are evaluated clinically and
subjected to laboratory and radiological investigations as per the designed
proforma. Data pertinent to the scoring systems will be recorded within
48hr of admission to the hospital. Once diagnosis is established the
patient disease severity will be assessed by following the scoring systems
CT SEVERITY INDEX, MODIFIED GLASGOW, BISAP. The accuracy
of each imaging and clinical scoring system for predicting the severity of
AP was assessed using appropriate statistical tools.
RESULTS: On keeping the cut of value for BISAP as 3, GLASGOW as
3 AND CTSI as 4 and analyzing using PEARSON CORRELATION it
was found BISAP had 82.6% correlation compared to GLASGOW and
CTSI which only had 51.4% correlation. If BISAP score predicts the
disease to be severe then there is 82% positivity that the patient will have
acute severe pancreatitis. In CRAMER V test the strength of association
was found to be 0.826 for BISAP score which is very high for predicting
complications. In other words only 23.6% of people with negative BISAP
score will have complication. The strength of association for Glasgow
and CTSI was 0.514 which is moderate association and there is 64.7%
chance of false negativity with these scoring systems.
CONCLUSION: From this study, we conclude that the BISAP score
could be a simple and better clinical scoring system for the evaluation of
disease severity in acute pancreatitis than GLASGOW and CTSI.
1INTRODUCTION
               ACUTE PANCREATITIS is a reversible pancreatic parenchymal
injury with inflammation which presents with varied clinical
presentation, it mostly presents as mild self limiting disease but in about
10 – 20% of cases it presents with systemic complications which require
intensive care unit treatment or surgical interventions and mortality in
these cases can be as high as 30-40%.  Severe acute pancreatitis is now
found to be bi-phasic with  systemic inflammatory response syndrome
(SIRS) leading to Multi organ dysfunction syndrome (MODS) in the
initial week which if resolutes by natural defences or treated by
therapeutic intervention leads on to local pancreatic complications like
pancreatic necrosis, sepsis and MODS in the ensuing weeks.
              Practically we need to identify those patients who are more
likely to develop complications of pancreatitis and this led to the
development of scoring systems based on clinical and imaging criteria’s.
The rationale behind these scoring systems is to identify those high risk
patients and manage them appropriately.
            Scoring system in pancreas has been evolving ever since the
development of Ranson’s criteria in 1974. The other scoring system used
are Modified Glasgow scoring system, Acute physiology and chronic
health evaluation (APACHE I & II), Bedside index for severity of acute
pancreatitis (BISAP) and Balthazar grading and CT severity index.
2REVIEW OF LITERATURE
TABLE 1: LANDMARKS IN HISTORY OF PANCREAS
Herophilus  334B.C First person to document the existence of
pancreas
Rufus 100 A.D. Considered pancreas as part of omentum and
coined pancreas meaning all flesh
Galen Described blood supply of pancreas
Massa 1536 Suggested pancreas as a cushion for stomach to
rest on
Vesalius 1541 Proved that Galen description of pancreas was
correct and showed pictorial illustrations of
pancreas
Wirsung Main pancreatic duct named after him
Vater 1720 Explained about the anatomy of duodenal
papillae
Santorini 1724 Described accessory pancreatic duct along with
other ducts
Morgagni 1769 Pancreatic malignancy – described
adenocarcinoma
Soemmering 1791 Called it abdominal salivary gland
Treitz 1853 Identified trietz band and retropancreatic fascia
Langerhans 1869 Identified small round cells scattered
throughout pancreas which was later named
after him
3MacBurney 1878 Removed calculi by doing duodenotomy
Von
Winiwarter
1882 Pancreatic adenocarcinoma – first person to
operate
Oddi 1887 Illustrated duodeno-panctreatic ampulla
Fitz 1889 Pathophysiology of pancreatitis
Bayliss and
Starling
1902 Discovered secretin
Kocher 1903 Described surgical method of duodenal
mobilization
Fabozzi 1903 Explained tumours of islet cells
Kausch 1909 Performed the first successful
pancreatoduodenectomy
Banting and
Best
1922 Isolated "insuline" from islet secretions of dog
pancreas
Elman 1927 Invented the serum amylase test
Whipple 1930 Offered his triad in insulinoma: 1) symptoms of
hypoglycemia during fasting; 2) serum glucose
less than 50 mg/dL; 3) with administration of
exogenous glucose the hypoglycemic
symptoms disappear
Whipple 1940 Performed a one-stage excision of the entire
head of the pancreas with total duodenectomy
with 10-year survival
Rockey 1943 Performed the first total pancreatectomy
Doubilet and
Mulholland
1965 Advocated sphincterotomy to treat acute
pancreatitis
4Kelly and
Lillehei
1966 First clinical pancreas transplant
Fortner 1973 Described regional pancreatectomy
Traverso and
Longmire
1978 Introduced the pylorus-preserving
pancreatoduodenectomy
Beger et al. 1988 Described necrosectomy in management of
necrotizing pancreatitis
EMBRYOGENESIS OF PANCREAS
          Genesis of pancreas begins at the end of fourth week of intrauterine
gestation. It develops from the dorsal and the ventral primordium. The
ventral primordium forms the duct of Wirsung, part of uncinate process
and the head. The dorsal primordium forms duct of santorini, remainder
of uncinate process and the body and tail. Both the dorsal and ventral
primordium fuse at the sixth week. Secretion of insulin begins at fifth
month.
Failure of fusion of dorsal and ventral pancreatic buds results in
Pancreatic divisum. In this condition main and accessory pancreatic duct
drain separately. Pancreatitis is a common complication of this anomaly.
Annular pancreas is another anomaly of pancreas where second
part of duodenum is surrounded by a band of pancreatic tissue causing
5stenosis at that level. Other congenital conditions include Heterotrophic
pancreatic tissue, Accessory pancreas and pancreatic gall bladder.
SURGICAL ANATOMY OF PANCREAS
Pancreas is one of the treacherous organs to operate on because
often its location. It is a retroperitoneal organ which is closely related to
the duodenum stomach, spleen, transverse mesocolon, great vessels and
omental bursa.
Pancreas can be divided into four parts  head, neck, body and tail.
Head of pancreas is flattened antero-posteriorly with its anterior surface
related to pylorus and transverse colon and the posterior surface related to
right kidney, right crus of diaphragm,  inferior vena cava, and right
gonadal vessels. Head of pancreas is lies adherent to C loop of
duodenum.
6The word uncinate means hook like. It is a projection from the
head of pancreas with highly variable anatomy. On cut section, it is
located between aorta and superior mesenteric vessels with left renal vein
above and third part of duodenum below.
The pancreatic tissue between the passage of superior mesenteric
vessels and the beginning of portal vein dorsally is the neck of pancreas
which is 1.5 to 2 cm long. It is anteriorly related to the gastroduodenal
artery giving rise to superior pancreatico-duodenal artery and posteriorly
related to portal vein formed by confluence of superior mesenteric and
splenic vein.
Body of pancreas is related to the lesser omentum of stomach and
transverse mesocolon  anteriorly and posteriorly related to origin of
superior mesenteric artery, left renal and suprarenal gland, and splenic
vein.
7The tail is related to hilum of spleen and is enclosed along with
splenic artery and splenic vein in splenorenal ligament.
PANCREATIC DUCTAL ANATOMY
The duct of wirsung starts from the tail and is situated midway
between superior and inferior margins and more posterior than anterior.
In about 50% of cases it crosses the first lumbar vertebrae. The tributaries
enter at right angles to the main pancreatic duct in tail and body of
pancreas and the superior and inferior pancreatic tributaries alternate with
each other. The approximate number of tributaries is 15-20.
The main duct turns caudal and posterior at the level of head of
pancreas and on reaching major papillae it becomes horizontal and joins
posterior surface of CBD and enters wall of duodenum at the level of
second lumbar vertebra. The diameter of the duct varies from head to tail.
Usually it is largest at the head and narrowest at the tail. It is
approximately 3mm at the head, 2mm in body and 1mm in tail of
pancreas.
The accessory duct of santorini drains the superior portion of head
and is smaller in size than the main duct. It usually drains into minor
duodenal papillae but can sometimes join the main duct.
8PAPILLA OF VATER AND AMPULLA OF VATER
The major duodenal papilla otherwise known as papilla of vater is
a mound like projection in the second part of duodenum through which
the distal portion of ampulla passes into duodenum. Bidloo in 1685 first
illustrated papilla but the structure bears the name of Abraham Vater.
The papilla of vater is located posteromedially approximately at
the level of second lumbar vertebrae in the second portion of duodenum.
Endoscopically it can be identified where longitudinal and transverse
folds meet forming a T-shaped mucosal fold.
Ampulla is the name given to the dilatation of the common
pancreaticobiliary channel. There can be three variations in ampulla
anatomy, they are
91. Pancreatic duct opens into CBD at a variable distance from
papilla with or without dilatation
2. Pancreatic and bile duct open near one another into major
duodenal papillae
3. Pancreatic and duodenal papillae open separately into
duodenum
The minor papilla is 2cm superior to the major papilla and the
landmark for identification is gastroduodenal artery. The blood supply of
ampulla of vater is from the posterior superior pancreaticoduodenal
arteries (PSPD) and from arcade arising from postero superior and
posteroinferior pancreatic arteries.
The sphincter of boyden includes smooth muscle fibers from
intramural part of bile duct, pancreatic duct, ampulla and from duodenal
musculature. The sphincter guarding the ampulla is cut during
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sphincterotomy at 11’0 clock position to avoid damage to vessels. The
vessels that can get commonly damaged are retroduodenal and
anamolous right hepatic artery. To avoid injuring it is better to palpate
posteriorly and look for any pulsation, which if present will indicate
anomalous artery.
BLOOD SUPPLY OF PANCREAS
The blood supply of pancreas is complex, variable and atypical.
The arterial supply of pancreas comes from both celiac plexus and
splenic artery of which the splenic artery forms the major blood supply.
Anterior and posterior superior pancreatico duodenal artery  arising from
gastroduodenal artery anastamose with anterior and posterior inferior
pancreatico duodenal artery arising from superior mesenteric artery. This
anastamotic arcade supplies the head of pancreas and duodenal wall.
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The gastroduodenal artery which is a branch of common hepatic
artery gives rise to supraduodenal , gastroduodenal and  superior
pancreatico duodenal arteries. The anterior superior pancreatico duodenal
(ASPD) artery gives eight to ten branches to anterior surface of pancreas
and anastamose with anterior inferior pancreatico duodenal artery.
Supraduodenal and retroduodenal arteries supply the first part of
duodenum. The posterior arcade lies away from duodenum posterior to
lower end of Common bile duct. Injury to the ASPD can occur during
puestow procedure.
The splenic artery gives rise to dorsal pancreatic artery which in
turn gives origin to transverse or inferior pancreatic artery, the great
pancrteatic artery or pancreatic magna and the caudal pancreatic artery
sometimes. The course of splenic artery above the body and tail pancreas
is tortuous. Failure of anastamosis of inferior pancreatic artery with
gastroduodenal artery can cause necrosis of tail if blocked by emboli.
Pancreatic surgeon should be aware of anomalous hepatic arteries and
anomalous middle colic arteries during surgery.
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The venous drainage of pancreas follows the arterial supply and
they lie superficial to the artery. The drainage is to the portal vein, splenic
vein, superior and inferior mesenteric veins. Both artery and vein lie
posterior to the ducts.  There are usually no branches on the anterior
surface of portal vein.
LYMPHATIC DRAIANGE OF PANCREAS
 The lymphatics from pancreas drain into five main groups which
are anterior, posterior, superior, inferior and splenic nodes. The superior
group drains from upper half of head and body of pancreas. The inferior
group drains the lower half of head and body of pancreas. The splenic
group predominantly drains tail of pancreas.
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NERVE SUPPLY
Pancreas gets both sympathetic and parasympathetic innervations.
The sympathetic innervations are from preganglionic greater and lesser
thoracic splanchnic nerves which relay into celiac and superior
mesenteric ganglion. Postganglionic  branches from this ganglia supply
pancreas by accompanying major blood vessels. The parasympathetic
innervations is via the vagus.
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HISTOLOGY AND PHYSIOLOGY OF PANCREAS
Pancreas is a mixed exocrine and endocrine gland which does not
have a definitive capsule but surrounded by fine connective tissue. The
islets of langerhans are scattered throughout pancreas (constitute 2% of
gland tissue). The exocrine portion of pancreas is composed of dark
staining acini which are in arranged as tubular and spherical masses
forming subunits of lobule.
In response to a meal the acinar cells undergo cyclical changes in
morphology. With the help of electron microscopy subcellular structures
in acinar cell can be studied. The acinar cells has short slender microvilli
extending into lumen of acinus. The golgi complex which plays an
important role in the formation of zymogen granules and the transport of
secreting proteins is situated between nucleus and the mass of zymogen
granules in resting gland. There are two types of secretory granules in
pancreas, electron dense zymogen granules and electron lucent
condensing vacuoles. Zymogen granules are membrane bound spherical
vesicles containing the digestive enzymes.   The functional unit of
exocrine pancreas is the acinus and its draining ductile which in turn joins
the intercalated ducts which finally drains into main pancreatic duct.
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Exocrine pancreatic secretions include both inorganic and organic
secretions. The inorganic secretion constitutes water, sodium, potassium,
bicarbonate and chloride. The average secretion is around 800 to 1000ml
per day. The flow rate increases from 0.3ml/minute to 4.0 ml/minute
during meal. Secretin stimulation causes increased volume of pancreatic
fluid. Pancreatic enzymes originate in the acinar cells. Secretion of water
and electrolytes originates in the centroacinar and intercalated duct cells.
Centroacinar cells and ductular epithelium secrete 20 mmol of
bicarbonate per liter in the basal state. Major stimulants are Secretin,
Cholecystokinin, Gastrin and Acetylcholine. Major inhibitors are
Atropine, Somatostatin, Pancreatic polypeptide and Glucagon. Secretin is
released from the duodenal mucosa in response to a duodenal luminal
pH < 3.
Amylase is the only digestive enzyme secreted by the pancreas in
an active form. It functions optimally at a pH of 7 and hydrolyzes starch
and glycogen to glucose, maltose, maltotriose, and dextrins. Lipase
functions optimally at a pH of 7 to 9 emulsify and hydrolyze fat in the
presence of bile salts. Proteases are essential for protein digestion which
are secreted as proenzymes and require activation for proteolytic activity.
The duodenal enzyme enterokinase converts trypsinogen to trypsin.
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Trypsin in turn, activates chymotrypsin, elastase, carboxypeptidase, and
phospholipase .
The following table shows the various digestive enzymes secreted
by pancreas.
TABLE 2 – DIGESTIVE ENZYMES OF PANCREAS
Proenzymes* Cationic trypsinogen
Anionic trypsinogen
Mesotrypsinogen
Chymotrypsinogen (A, B)
Kallireinogen
Procarboxypeptidase A (1, 2)
Procarboxypeptidase B (1, 2)
Prophospholipase
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Proelastase
Enzymes Amylase
Carboxylesterase
Sterol esterase
Lipase
DNase
RNase
The regulation of pancreatic enzyme secretion is mediated via both
humoral and neural pathways. In addition to the enzymes pancreatic
trypsin inhibitor is produced which prevents auto catalytic digestion of
pancreas and henceforth pancreatitis.
There are about one million islet cells in the pancreas, each
measuring 0.2mm in diameter and surrounded by a rich network of
capillaries with fenestrated endothelium. The acinar cells surrounding the
islets are called peri islet acinar cells which are biochemically different
from tele acinar cells (located away from islet cells).  Insulin Synthesized
in the Beta cells of the islets of Langerhans is the only hormone reducing
the blood glucose level. Proinsulin is transported from the endoplasmic
reticulum to the Golgi complex where it is packaged into granules and
cleaved into insulin and a residual connecting peptide, C peptide. Major
inhibitors are somatostatin, amylin, pancreastatin and ?-sympathetic
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fibers. Major stimulants are Glucose, amino acids, glucagon, GIP, CCK,
sulfonylurea compounds, ?-Sympathetic fibers. 80% of the islet cell mass
must be surgically removed before diabetes becomes clinically apparent.
Glucagon is secreted by the A cells of the islet. Glucagon elevates
blood glucose levels through the stimulation of glycogenolysis and
gluconeogenesis Major stimulants are Aminoacids, Cholinergic fibers
and ?-Sympathetic fibers. Major inhibitors are Glucose, insulin,
somatostatin and ?-sympathetic fibers.
D cells of the islet secrete somatostatin which inhibits the release
of growth hormone and release of almost all peptide hormones. It also
inhibits gastric, pancreatic, and biliary  secretion. It is used to treat both
endocrine and exocrine disorders.
ACUTE PANCREATITIS
Terms and definitions:
When acute it is often a mortal ill.  It strikes the patient suddenly
and often, strikes to kill. These are the words of Zachary cope regarding
pancreatitis.
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It is an auto digestion of the pancreatic and peripancreatic tissues
resulting in local and systemic manifestations, many of which are
catastrophic and fatal.
Mild acute Pancreatitis: Minimal organ dysfunction responsive to
fluid administration. Severe acute pancreatitis: One of the following:
Local complications (Pancreatic necrosis, Pancreatic pseudocyst,
Pancreatic abscess), Organ failure, Ranson criteria >3 or APACHE II> 8
points.
Acute fluid collections: Fluid collections in or near the pancreas
which occurs early in the course charaterized by lack a defined wall.
Pancreatic necrosis: Non viable pancreatic tissue diagnosed by IV
CECT. Acute pseudocyst: Fluid collection containing pancreatic
secretions with a defined wall. Pancreatic abscess: Collection of pus
usually in or near pancreas.
In general gastroenterologist uses the Atlanta classification to grade the
severity of pancreas.
Atlanta Criteria for Severe Acute Pancreatitis
 Organ Failure
a. Shock: systolic blood pressure <90 mm Hg
b. Pulmonary insufficiency: Pao2??60 mm Hg
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c. Renal failure: serum creatinine >2 mg/Dl
d. Gastrointestinal bleeding: >500 mL/24 hr
 Local Complications
a. Necrosis
b. Abscess
c. Pseudocyst
Unfavorable Early Prognostic Signs
a. Ranson's signs (see Table 58-2)
b. APACHE-II points
NATURAL HISTORY:
The disease process seems to involve two phases. The first phase is
related to the inflammatory cascade that usually lasts for a week. During
this phase extrapancreatic organ failure secondary to systemic
inflammatory response is elicited by acinar cell injury. Infection is rare in
this phase.  Fever, tachyacardia, hypotension, tachypnoea, and
leukocytosis are typically seen. This phase can resolute with some
amount of pancreatic edema or progress to irreversible liquefactive
necrosis or form fluid collections in and around pancreas. The severity of
organ failure and the extent of pancreatic or peripancreatic involvement is
directly propotional.
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Nearly 25% of cases develop a more protracted disease course
without undergoing resolution. The second phase of pancreatitis is the
development of necrotizing pancreatitis. This phase is complicated by
sepsis and multiorgan failure. The mortality in pancreatitis is common
during first week and later during the third week due to infection in
pancreatic necrosis. Mortality is higher in older, comorbid patients than
younger population.
PATHOPHYSIOLOGY:
The pathophysology of pancreatitis on the basis of Autodigestion
theory suggests that proteolytic enzymes are activated within the
pancreas rather than in the intestinal lumen. The trypsin enzyme activated
causes a cascade of other enzymes to be activated initiating pancreatitis.
Normally there are certain intrapancreatic mechanisms causing
inactivation of trypsin, they are the pancreatic secretory trypsin inhibitor
now known as SPINK 1, mesotrypsin, peptide-y and trypsin itself. They
are also certain non specific proteases like alpha-1-antitrypsin and alpha-
2-macroglobulin. When the amount of activated trypsin overhelms the
defence mechanism pancreatitis ensues. Trypsin activated peptide
concentration in urine and ascitis fluid correlates with the severity of
pancreatitis.
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INITIAL PHASE is characterized by acinar cell injury due to
intrapancreatic digestive enzyme activation.  Zymogen activation
mediated by lysosomal hydrolases e.g. cathepsin B
SECOND PHASE constitutes Intrapancreatic inflammation reaction
due to activation, chemoattraction, and sequestration of neutrophils in the
pancreas. This neutrophil sequestration can activate trypsinogen
In the THIRD PHASE activated proenzymes, (esp. Trypsin)  digest
pancreatic and peripancreatic tissues and  activate other enzymes (i.e.
elastase, phospholipase) due to effects of activated proteolytic enzymes
and cytokines, released by inflamed pancreas, on distant organs, most
notably the lungs which may result to SIRS and ARDS, and  Multiorgan
failure.
The second theory of co-localization of enzymes states that co
localization of pancreatic enzymes in lysosome causes acinar cell injury
which leads to pancreatitis. Cathepsin b is responsible for co-localization
of enzymes and inhibitor of Cathepsin b may prevent trypsinogen
activation and therby pancreatitis. In experimental models the disruption
of paracellular barrier of acinar and duct cells cause extravasation of
enzymes into interstitial spaces causing interstitial edema.
The activation of the enzymes leads to microcirculatory injury,
leukocyte chemoattraction followed by release of cytokines, free radical
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production, pancreatic fluid accumulation and bacterial transmigration to
pancreas leading to systemic sepsis. Microcirculatory changes are
vasoconstriction with stasis and hence decreased oxygen saturation, and
progressive ischemia.
This microcirculatory failure leads to release of proinflammatory
cytokines such as Tumour necrosis factor, interleukin -1, 6, 8 and platelet
activating factor.  The next step is the formation of reactive oxygen
species which further aggravates microcirculation leading to increased
vascular permeability and henceforth thrombosis and haemmorhage
ending up in pancreatic necrosis.
Systemic complications in pancreatitis include fever, ARDS,
metabolic complications, pleural effusion, renal failure, myocardial
depression and shock. The pancreatic enzymes (phospholipase, elastase,
trypsin) and cytokines (tumour necrosis factor, platelet activating factor)
which get released into portal circulation cause systemic inflammatory
response syndrome. The cytokines on reaching liver causes acute phase
protein synthesis namely C-reactive protein and IL-6.
Acute respiratory distress syndrome is mainly due to
phospholipase A which degrades the lung surfactant. Renal failure is a
result of hypovolemia and hypotension. Metabolic complications are
hyperlipidemia, hyperglycemia with or without ketosis, hypoglycemia
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and  hypocalcemia which in turn is mainly due to hypoalbuminemia ,
hypomagnesia and soap formation.
Infective necrosis and infective psuedocyst is mainly due
translocation of bacteria from gut due breakdown of immunological
barriers and ischemia of gut wall as a result of arteriovenous shunting of
blood. Infection can also come via hematogenous route.
PREDISPOSING CONDITIONS
The number of conditions predisposing to pancreatitis is growing day by
day
Metabolic:
? alcoholism
? hyperlipoprotienemia
? hypercalcemia
? drugs
? genetic
Mechanical:
? trauma
? iatrogenic injury
? endoscopic procedure & perioperative injury.
Vascular:
? shock
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? athero embolism
? polyarthritis nodosa
? SLE
? HSP
Infectious:
? mumps
? coxsackie virus
? mycoplasma
Obstruction of biliary duct:
? periampullary tumour
? gall stone
? pancreatic divisum
? choledochocele
? ascaris lumbricoides
? clonorchis sinensis
Genetic:
? cationic trypsinogen
? trypsin inhibitor
Less common causes
? Pancreas divisum
? Chinese liver fluke
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? Ischemia (bypass surgery)
? Cystic fibrosis
OBSTRUCTIVE CAUSES
? GALLSTONES
Along with alcohol it forms one of the most common causes of
pancreatitis. Only 3-7% of patients with gallstones get pancreatitis. More
common in stones which are less than 5mm as they can pass through
cystic duct and cause ampullary obstruction. Recurrence of pancreatitis
can be prevented by cholecystectomy and clearance of stones from
common bile duct.
? BILIARY SLUDGE AND MICROLITHIASIS
Stones less than 3mm are known as microlithiasis, which usually
hide in a viscous suspension of bile called biliary sludge. Biliary sludge
composed of calcium monohydrate or calcium bilirubinate is usually
asymotomatic but association with pancreatitis is proven in some studies.
It appears as a low amplititude echo on ultrasound without characteristic
acoustic shadow of gall stone. Biliary sludge can be due to prolonged
fasting, ceftriaxone administration and total parenteral nutrition. At
present no consensus are present on treatment protocol for biliary sludge.
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? TUMOURS
Intraductal papillary mucinous neoplasm is the most common
tumout causing pancreatitis, pancreatic adenocarcinoma can also cause
pancreatitis rarely.
? OTHER OBSTRUCTIVE CAUSES
Annular pancreas, choledochocele, duodenal diverticula, and
parasites like ascaris and clonorchis obstruct the pancreatico-biliary
system .
ALCOHOL, TOXINS AND DRUGS
The effects of ethyl alcohol are modulation of pancreatic exocrine
secretion  in such a way that lithogenicity of pancreatic juice increases
and causes stone formation, Contraction of sphinter of oddi, direct toxic
effects on acinar cell, Directly activating trypsinogen,and  Oxitative
stress / free radicles formation. Usually alcohol causes chronic pancretitis
but episodes of acute pancreatitis can be seen. The fatty acid ester of
ethyl alcohol is the toxic metabolite. Another hypothesis is the de novo
fibrosis of pancreas which states that cytokines stimulate stellate cells
which in turn cause periductal fibrosis and thereby ductal obstruction and
stone formation. In acute pancreatitis due to alcohol if inciting factors are
removed then pancreatitis resolves spontaneously.
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Table  3 -- Drugs Associated with Acute Pancreatitis
? Acetaminophen
? Alphamethyldopa
? 5-Aminosalicylic acid compounds
? Sulfasalazine
? Azodisalicylate
? Mesalamine
? Carbimazole
? Cimetidine
? Clozapine
? Dapsone
? Dexamethasone
? Enalapril
? Erythromycin
? Estrogen
? Furosemide
? Hydrochlorothiazide
? Hydrocortisone
? Isoniazid
? Lamivudine
? Losartan
? Metronidazole
? Nelfinavir
? Simvastatin
? Sulfamethazole
? Tetracycline
? Trimethoprim-sulfamethoxazole
? Valproic acid
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Drugs can cause pancreatitis by three mechanisms hypersensitivity, Toxic
metabolite and  intrinsic toxicity.
METABOLIC DISORDERS
? HYPERTRIGLYCERIDEMIA
It is the third most common cause of acute pancreatitis after stone and
alcohol. Serum triglyceride concentration greater than 1000mg/dl causes
pancreatitis. It is Commonly seen in children with inherited
hypertriglyceridemia and lipoprotein metabolism. Type I, II and V
hypertryglyceridimia patients are more prone to attacks of pancreatitis
and to prevent this lipoprotein should be less than 200mg/dl. Some of
these patients may not manifest until an acquired trigger in the form of
diabetes, alcohol or drugs is present.
? HYPERCALCEMIA
Increase in serum calcium can cause activation of trypsinogen within
pancreatic duct and thereby pancreatitis. But usually hypercalcemia is
rarely associated with pancreatitis and sometimes can occur in
hypercalcemia due to hyperparathyroidism, metastatic bone disease,
vitamin D toxicity and sarcoidosis.
? INFECTIONS
Radiological or tissue evidence of inflammation in pancreas is known
as definite pancreatitis. Biochemical elevation of serum lipase or amylase
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with symptoms is called probable pancreatitis and asymptomatic patients
with only biochemical evidence are known as possible pancreatitis.
Organisms associated with definite pancreatitis are Viruses (mumps,
coxsackievirus, hepatitis B, , hepatitis A, hepatitis C, cytomegalovirus,
varicella-zoster, herpes simplex and Epstein-Barr); bacteria
(Mycoplasma, Salmonella, tuberculosis, Legionella, Leptospira, ,and
brucellosis); fungi (Aspergillus and Candida albicans); and parasites
(Toxoplasma, Cryptosporidium, Ascaris, Clonorchis sinensis. A Defienite
criterion to define an organism as a cause of pancretitis is to do a culture
or stain of organism in pancreas or duct.
• VASCULAR DISEASE
Ischemia of pancreas can occur due to vasculitis, emboli from
atheromatous plaques, hemorrhagic shock, or after cardiopulmonary
bypass. The end result of ischemia is mild pancreatitis or fatal necrotizing
panctreatitis.
• TRAUMA
Pancreatitis can occur both due penetrating trauma and blunt trauma
and the injury can range from contusion to transection of gland. In blunt
injury the transaction commonly occurs at the place where the duct
crosses the spine. The management depends on the extent of adjacent
organ injury and ductal involvement or not.
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Table 4 -- Factors That Increase the Risk of Post-ERCP Pancreatitis
Patient Related
Young age, female gender, suspected sphincter of Oddi dysfunction,
recurrent pancreatitis, history of post-ERCP pancreatitis, normal serum
bilirubin
Procedure Related
Pancreatic duct injection, difficult cannulation, pancreatic sphincterotomy,
precut access, balloon dilation
Operator or Technical Related
Trainee (fellow) participation, nonuse of a guidewire for cannulation,
nonuse of a pancreatic duct stent in high-risk procedures
Early recognition of post-ERCP pancreatitis can be done by serum
amylase or lipase measurement. Lot of studies on drugs to cause
relaxation of sphincter of oddi have not proven beneficial. Proposed
methods to decrease the risk of pancreatitis are pancreatic stent
placement, usage of guidewire for cannulation and avoiding precut
sphinctrotomies.
• POST-ERCP
Acute pancreatitis is one of the feared complications of ERCP. The
pathophysiology of post-ERCP acute pancreatitis is multifactorial and
depends on factors like chemical, thermal, mechanical, enzymatic and
hydrostatic.
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• CONGENITAL CAUSES
Hereditary pancreatitis is a genetic disease that causes childhood
pancreatitis and increased risk for pancreatic malignancy. Other
controversial causes are pancreatic divisum and sphincter of oddi
dysfunction.
CLINICAL FEATURES
Abdominal pain is the major symptom in pancreatitis and it varies
from mild to severe constant pain which is steady and boring in character
located in epigastrium and periumbilical radiating to the back, chest,
flank and lower abdomen. Pain more intense on supine, relieved by
sitting.Pain  usually occurs after intake of alcohol. Other features are
vomiting and fever (inflammatory mediators), Mild jaundice
(cholangitis), Oliguria, hypoxia, acidosis, shock and dehydration.
Erythematous skin nodules and in about 10-20% of patients- basilar rales,
atelectasis and pleural effusion are also present.
Clinical signs include tachycardia, tachypnoea, tenderness,
gaurding, rigidityand abdominal distension due to ileus or ascites. Grey
turner’s sign occurs due to enzymes seepage across retroperitoneum
causing haemorrhagic spots and ecchymosis in the flanks. Cullen’ sign is
Ecchymosis and discolouration around umblicus (umblical black eye) and
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fox sign is Ecchymosis and discolouration below the below inguinal
ligament.
Some physical findings suggest a specific cause of acute
pancreatitis. Hepatomegaly, spider angiomas, and  palmar thickening
favor alcoholic pancreatitis. Eruptive xanthomas and lipemia retinalis
suggest hyperlipidemic pancreatitis. Parotid pain and swelling are
features of mumps. Band keratopathy (an infiltration on the lateral
margin of the cornea) occurs with hypercalcemia.
LAB INVESTIGATIONS
Serum amylase, more specifically isoenzyme- P is increased more
than two to three fold in pancreatitis. Does not parallel the severity of
attack, it rises in 2 to 6hrs, and declines after 3-6 days. Rising titre>1000
somogyi unit is significant.  Limitation of serum amylase is that it is not
100% sensitive or specific.  Urinary amylase remains elevated for longer
period. Serum amylase can be falsely normal in hypertriglyceridemia-
associated pancreatitis because of an amylase inhibitor.
Hyperamylasemia is not specific for pancreatitis and hence it is only a
supportive tool in diagnosis. It is also elevated in salivary gland diseases,
fallopian tube diseases, ovarian tumours, hollow viscus perforation and
many more. Macroamylaemia is a condition where serum amylase is
elevated but urinary amylase is normal. It is due to large amylase
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molecules bound to immunoglobulins seen in circulation and not filtered
through kidney. To rule out this urinary amylase to creatinine clearance
ration is seen. Urine amylase/serum amylase x serum creatinine/urinary
creatinine x 100. Normal value is 1-4%, >6% indicates acute pancreatitis.
It is also helpful to differentiate munchausen syndrome.
Serum Lipase is found predominantly in pancreas but also in gastric,
intestinal mucosa and liver. It is cleared by the kidney and hence renal
failure will lead to elevated levels. Most appropriate cut-off is 2-3 x
normal level. More accurate test than amylase, better specificity (90% vs.
75%)
Other parameters include Serum lactescence which is related to
triglyceride   metabolism and most specific in hypertryglycedimia. Serum
trypsin is a more accurate indicator. Serum calcium is measured to detect
hypocalcemia due to saponification. Trypsinogen activation polypeptide -
serum &urine assay, phospholipaseA2, LDH, CRP>150 mg/l are all
markers elevated in pancreatitis.
Routine investigations like Liver function tests, Renal function
test,  Blood sugar (Hyperglycemia), Total count, Haematocrit, Platelet
count,  Coagulation profile,  Arterial PO2and PCO2-  to assess
pulmonary insufficiency (ARDS) should all be done. Peritoneal tap - high
amylase, protein level and lipase level indicate pancreatic ascites.
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Methemalbuminemia -indicate poor prognosis. Inflammatory mediators
& acute phase reactants (IL1, IL6, TNF, CRP) predicts the severity of
disease.
Apart from the battery of investigations mentioned above certain
standard investigations should also be done. These include white blood
cell count which is often markedly elevated in severe pancreatitis, blood
glucose,Serum aspartate transaminase (AST), alanine aminotransferase
(ALT), alkaline phosphatase, and bilirubin also may increase, particularly
in gallstone pancreatitis. The erythrocyte mean corpuscular volume
(MCV) tends to be higher in alcoholic patients and hence shown to help
differentiate alcoholic from nonalcoholic acute pancreatitis. Serum
triglyceride levels increase in acute pancreatitis, but also with alcohol
use, uncontrolled diabetes mellitus, or defective triglyceride metabolism.
DIAGNOSTIC IMAGING
ABDOMINAL X- RAY
The findings on a plain radiograph vary from no abnormalities in mild
disease to localized ileus of a segment of small bowel (“the sentinel
loop”) or the colon cut-off sign in more severe disease. Added advantage
is an abdominal plain film helps exclude other causes of abdominal pain,
such as  obstruction and perforation.. Gastric abnormalities are caused by
exudate in the lesser sac producing anterior displacement of the stomach,
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thereby separation of the contour of the stomach from the transverse
colon. Small intestinal abnormalities are due to exudate in proximity to
small bowel mesentery and include ileus of one or more loops of jejunum
(the sentinel loop), of the distal ileum or cecum, or of the duodenum.
Generalized ileus may occur in severe disease.
Besides ileus, other abnormalities of the hollow GI tract may be
present. The descending duodenum may be displaced and stretched by an
enlarged head of the pancreas. In addition, spread of exudate to specific
areas of the colon may produce spasm of that part of the colon and either
no air distal to the spasm (the colon cut-off sign) or dilated colon
proximal to the spasm. Head-predominant pancreatitis predisposes to
spread of exudate to the proximal transverse colon, producing colonic
spasm and a dilated ascending colon. Uniform pancreatic inflammation
predisposes spread of exudate to the inferior border of the transverse
colon and an irregular haustral pattern. Exudate from the pancreatic tail to
the phrenicocolic ligament adjacent to the descending colon may cause
spasm of the descending colon and a dilated transverse colon.
Other findings on plain radiography of the abdomen may give
clues to etiology or severity, including calcified gallstones (gallstone
pancreatitis), pancreatic stones or calcification (chronic pancreatitis with
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a bout of acute inflammation), and ascites (severe pancreatitis). Gas in
the retroperitoneum may suggest a pancreatic abscess.
CHEST RADIOGRAPHY
The findings on the chest roentgenogram occur in 30% of patients
with acute pancreatitis, including elevation of a hemidiaphragm, pleural
effusion(s), basal or plate-like atelectasis secondary to limited respiratory
excursion, and pulmonary infiltrates. Pleural effusions may be bilateral or
confined to the left side; rarely they are only on the right side. Patients
with acute pancreatitis found to have a pleural effusion and/or infiltrate
on admission are more likely to have severe disease. During the first 7 to
10 days, there also may be signs of congestive heart failure or acute
respiratory distress syndrome. Pericardial effusion is rare.
ABDOMINAL ULTRASOUND
Abdominal ultrasonography is used during the first 24 hours of
hospitalization to search for gallstones, dilation of the bile duct due to
choledocholithiasis, and ascites. If the pancreas is identified (bowel gas
obscures the pancreas 25% to 35% of the time), it is usually diffusely
enlarged and hypoechoic. Less frequently there are focal hypoechoic
areas. There also may be ultrasonographic evidence of chronic
pancreatitis, such as intraductal or parenchymal calcification and dilation
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of the pancreatic duct. Ultrasound is not a good imaging test to evaluate
extrapancreatic spread of pancreatic inflammation or necrosis within the
pancreas and consequently is not useful to ascertain severity of
pancreatitis. During the course of acute pancreatitis, ultrasound can be
used to evaluate progression of a pseudocyst (discussed later). Due to
overlying gas, the diagnosis of cholelithiasis may be obscured during the
acute attack but may be found after bowel gas has receded.
COMPUTED TOMOGRAPHY
CT is the most important imaging test for the diagnosis of
acute pancreatitis and its intra-abdominal complications. The three main
indications for a CT in acute pancreatitis are to exclude other serious
intra-abdominal conditions, such as mesenteric infarction or a perforated
ulcer; to stage the severity of acute pancreatitis; and to determine whether
complications of pancreatitis are present, such as involvement of the GI
tract or nearby blood vessels and organs, including liver, spleen, and
kidney. Helical CT is the most common technique. If possible, scanning
should occur after the patient receives oral contrast, followed by
intravenous contrast to identify any areas of pancreatic necrosis. If there
is normal perfusion of the pancreas, interstitial pancreatitis is said to be
present. Pancreatic necrosis manifested as perfusion defects after
intravenous contrast may not appear until 48 to 72 hours after onset of
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acute pancreatitis. Contraindications to using intravenous contrast are a
patient's history of severe allergy (respiratory distress or anaphylaxis) or
significant renal impairment (serum creatinine greater than 2 mg/dL). If
severe renal impairment requires dialysis, intravenous contrast medium
may be used. Hives or less severe allergic reactions with previous
administration of iodinated contrast material are not absolute
contraindications, but a nonionic contrast agent should be used, and 200
mg of hydrocortisone should be administered intravenously every six
hours for four doses starting before the scan and 50 mg of
diphenhydramine (Benadryl) should be given intramuscularly 30 minutes
before the scan.
CT SHOWING EDEMATOUS PANCREAS WITH FLUID
COLLECTION
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CT SHOWING GAS POCKETS DUE TO STERILE NECROSIS
C
CT SCAN SHOWING NON- ENHANCING PANCREAS
SUGGESTIVE OF NECROSIS
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The severity of acute pancreatitis has been classified into five
grades (A to E) based on findings on unenhanced CT. Although the
presence of gas in the pancreas suggests pancreatic infection with a gas-
forming organism, this finding can also accompany sterile necrosis with
micro perforation of the gut or adjacent pseudocyst into the pancreas.
Moreover, the great majority of pancreatic infections occur in the absence
of gas on CT scan.
BALTHAZAR CT GRADING OF ACUTE PANCREATITIS
Prognostic Indicator Points Grade
Pancreatic inflammation
Normal pancreas
Focal or diffuse enlargement of the pancreas
Intrinsic pancreatic abnormalities with inflammatory
changes in peripancreatic fat
Single, ill-defined fluid collection or phlegmon
Two or more poorly defined collections or presence of
gas in or adjacent to the pancreas
Pancreatic necrosis
None
? 30%
> 30–50%
> 50%
0
1
2
3
4
0
2
4
6
A
B
C
D
E
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MODIFIED CT SEVERITY INDEX
        Points
Pancreatic inflammation
Normal pancreas
Intrinsic pancreatic abnormalities with or without
inflammatory changes in
peripancreatic fat
Pancreatic or peripancreatic fluid collection or
peripancreatic fat necrosis
Pancreatic necrosis
None
? 30%
> 30%
Extrapancreatic complications
(one or more of pleural effusion, ascites, vascular
complications, parenchymal complications, or
gastrointestinal tract involvement)
0
2
4
0
2
4
2
ENDOSCOPIC ULTRASOUND
Usually endoscopic ultrasonography (EUS) is not helpful early in
acute pancreatitis. Imaging of the pancreas during an attack of acute
pancreatitis and weeks following an episode reveal signals that are not
normal (typically hypoechoic) and indistinguishable from chronic
pancreatitis and malignancy. However, after a month, especially in
patients with idiopathic interstitial pancreatitis, EUS may help determine
the presence of small tumors, pancreas divisum, and bile duct stones.
EUS is equal to MRCP and ERCP but far more sensitive than either
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abdominal ultrasonography or CT in detecting common duct stones. In a
patient with biliary pancreatitis, whose serum bilirubin is rising in the
setting of biliary sepsis, ERCP should not be delayed by first performing
EUS. Although there has been some concern that ERCP can worsen
pancreatitis in such settings, ERCP appears to be safe in acute
pancreatitis if needed. One caveat is that the contrast instillation into the
pancreatic duct could introduce infection into necrotic areas of the
pancreas. For this reason, EUS might be the best method of evaluating
the bile duct in a patient with necrotizing pancreatitis.
MAGNETIC RESONANCE IMAGING
MRI provides similar information regarding the severity of
pancreatitis as does CT. MRI is as good as CT in detecting necrosis and
fluid collections. MRI is better than CT, but equal to EUS and ERCP in
detecting choledocholithiasis. The MRCP contrast agent gadolinium,
previously thought to be safe in patients with renal failure, can cause
nephrogenic systemic fibrosis (NSF), which has raised concern. MRI is
less accessible and more expensive than CT. MRI also requires the
patient to remain still during capture of images, which typically is longer
than with spiral CT. The use of intravenous secretin prior to MRCP
allows a better visualization of the pancreatic ducts. This has been shown
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to be particularly useful in the evaluation of patients with idiopathic
pancreatitis and recurrent pancreatitis.
PREDICTORS OF SEVERITY
Predicting severity of pancreatitis early in the course of disease is critical
to maximize therapy and to prevent and minimize organ dysfunction and
complications. Unfortunately the management of patients with acute
pancreatitis is complicated by the inability to distinguish mild from
severe disease during the early stages. The definition of the severity of
acute pancreatitis early in the course of disease (during the first week) is
typically based on clinical rather than anatomic parameters. At
admission, several potential risk factors of severity and measurements
that may reflect severity should be documented including age, body mass
index, elevated hematocrit, elevated blood urea nitrogen (BUN), and
pleural effusions or infiltrates on admission chest radiograph. The height
of elevation of the serum amylase and lipase does not correlate with
severity. Obese patients with pancreatitis have a higher incidence of local
complications, respiratory failure, severe acute pancreatitis, and death
from sterile necrosis than do nonobese patients.
Initially at presentation and over the first 48 hours, patients should be
classified temporarily as having severe acute pancreatitis (and managed
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as such initially) based on the presence of SIRS or organ failure. SIRS is
defined by two or more of the following four criteria: pulse greater than
90 beats/minute; rectal temperature less than 36C or more than 38C;
white blood count less than 4000 or more than 12,000/mm3; and
respirations greater than 20/minute or Pco2 less than 32 mm Hg. The
presence of SIRS at admission and persistence of SIRS to 48 hours
increases the morbidity and mortality rate. In one study, 25% of patients
with persistent SIRS died from acute pancreatitis, 8% with transient
SIRS, and less than 1% without SIRS.
Although severity is now defined by the presence of organ failure or
anatomic complications of acute pancreatitis, such as pancreatic necrosis,
prospective systems using clinical criteria have been developed to
determine severity in patients with acute pancreatitis. These systems
include Ranson criteria  and APACHE score. Unfortunately these scoring
systems (discussed following) are cumbersome, requiring multiple
measurements. Additionally, the systems are not accurate until 48 hours
after presentation.
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SCORING SYSTEMS
Ranson's Score
Ranson and colleagues identified 11 signs that had prognostic
significance during the first 48 hours. The original list was analyzed in
patients who primarily suffered from alcoholic pancreatitis and was then
modified 8 years later for those with gallstone pancreatitis. Higher
Ranson's scores predict more severe disease. In mild pancreatitis (scores
< 2), the mortality is 2.5% and in severe pancreatitis (scores > 3) the
mortality is 62%. Also, the higher the Ranson's score the higher the
incidence of systemic complications, necrosis, and infected necrosis.
These lists continue to remain in wide use in both the United States and
Europe.
The Ranson criteria have several drawbacks. First, the list is
cumbersome and there are two lists to follow depending on suspected
etiology. Second, an accurate Ranson's score takes 48 hours to compute
and the criteria have not been validated beyond the 48-hour time limit.
Third, not all laboratories measure all the parameters in routine blood
tests (e.g., serum lactate dehydrogenase [LDH]). Fourth, the overall
sensitivity of the Ranson criteria (using three signs as the cutoff) for
diagnosing severe disease is only 40% to 88% and the specificity is only
43% to 90%. The positive predictive value is approximately 50% and the
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negative predictive value around 90%. Therefore, the best use of
Ranson's score is to exclude severe disease.
CRITERIA FOR PANCREATITIS NOT DUE TO GALL STONES:
At admission or diagnosis:
       Age more than55 years
       WBC count > 16,000/mm3
       Blood sugar> 200 mg/dL
Serum LDH> 350 IU/L
AST > 250 U/dL
During initial 48 hours:
 Fall in hematocrit> 10 percentage points
       BUN elevation > 5 mg/dL
       Serum calcium level < 8 mg/dL
       Arterial Po2 less than 60 mm Hg
       Base deficit more than 4 meq/L
       Estimated fluid sequestration > 6 L
CRITERIA FOR PANCREATITIS DUE TO GALL STONES
On admission or diagnosis:
Age > 70 yrs
WBC count > 18,000/mm3
Blood sugar> 220 mg/dL
Serum LDH> 400 IU/L
AST > 250 U/dL
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During initial 48 hours:
       Fall in hematocrit greater than 10 percentage points
       BUN elevation > 2 mg/dl
       Serum ca2+ level < 8 mg/dl
       Base deficit more than 5 meq/L
       Estimated fluid sequestration > 4 L
APACHE-II Scores
APACHE-II is another commonly used scoring system in the United
States to predict severity. It has the advantage of being able to be used on
a daily basis and has similar positive and negative predictive values as the
Ranson score at 48 hours after admission. The APACHE-II system
assigns points for 12 physiologic variables, for age, and for chronic
health status, in generating a total point score. The 12 variables are
temperature; heart rate; respiratory rate; mean arterial blood pressure;
oxygenation; arterial pH; serum potassium, sodium, and creatinine;
hematocrit; white blood cell (WBC); and Glasgow Coma Scale.
APACHE-II scores on admission and within 48 hours help distinguish
mild from severe pancreatitis and to predict death. Most patients survive
if APACHE-II scores are 9 or less during the first 48 hours. However,
patients with APACHE-II scores of 13 or more have a high likelihood of
dying. At admission, sensitivity is 34% to 70%, and specificity is 76% to
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98%. At 48 hours, sensitivity remains less than 50%, but specificity is
close to 90% to 100%. Strong drawbacks are its complexity, its low
sensitivity on admission, and the fact that at 48 hours the score is no
better than other scoring systems.Like the Ranson criteria, the APACHE-
II score has its highest value in predicting mild disease.
BISAP
The problem with scoring systems is that they are cumbersome,
using multiple variables. As described above, accuracy in predicting
morbidity and/or mortality of the most commonly used scoring systems,
Ranson and APACHE, is typically not achieved until 48 hours. By this
time, it is usually apparent that the patient has developed severe disease
manifested by organ failure. In order to develop a simple scoring system
for patients with acute pancreatitis that would be useful within the first 12
hours  from  admission,  the  Pancreas  Center  at  Brigham  and  Women's
Hospital performed a series of studies retrospectively and prospectively.
The studies were performed on a large database including almost 37,000
patients and more than 200 hospitals. After careful analysis, including a
validation study, they determined that a simple system that included 5
variables could accurately determine severity early in the course of the
disease. The scoring system, referred to as BISAP (Bedside Index for
Severity in Acute Pancreatitis), also uses the first letter of each parameter
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for 1 point. The BISAP score provides a single point for 5 parameters:
blood urea nitrogen (BUN) greater than 25 mg/dL, impaired mental
status, systemic inflammatory response syndrome, age greater than 60,
and/or the presence of a pleural effusion, for a possible total of 5 points.
A BISAP score greater than 3 is associated with a seven- to twelve-fold
increase in developing organ failure. Accurate, yet much easier to use,
this new simple scoring system appears to be useful in the early
identification of patients who are at risk of developing complications and
mortality.
The BISAP includes:
1) Blood urea nitrogen (BUN) >25 mg / dl.
2) Impaired mental status (GCS < 15).
3) SIRS.
4) Age >60 years.
5) Pleural effusion.
SIRS was defined by presence of two or more of the following
criteria:
1) Pulse rate > 90/min.
2) Respiratory rate > 20/min or PaCO 2 < 32 mm Hg.
3) Temperature >100.4 F or < 96.8 F / < 36 or > 38 ° C.
4) WBC count >12,000 or < 4,000 cells/mm3, or presence of
more than 10% immature blasts.
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GLASGOW – IMRIE SCORE
Glasgow score is a slightly simplified list (eight criteria) that is
used commonly in the United Kingdom. It has similar drawbacks to the
Ranson score.
Within 48 hours
• WBC>15,000
• AST>300
• LDH>600
• Glucose>180
• BUN>45
• PaO2<60
• Calcium<2meq/l
• Albumin<3.2gms%
Advantage is easy to calculate and one need not wait for 48 hours
ORGAN FAILURE
There is considerable interest among pancreatologists in using
organ failure to predict severity. The Atlanta criteria defined which organ
systems are of importance: pulmonary, renal, and cardiovascular.
However, these criteria did not attempt to quantitate or prognosticate
using organ failure. It has been appreciated that multiorgan failure or
persistent single organ failure has a greater associated mortality than
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transient single organ failure. Multisystem organ failure is defined as two
or more organs failing on the same day, rather than one organ failing on
one day and another failing on the subsequent day. Patients with
multisystem organ failure or persistent organ failure have a much higher
mortality rate (approaching 50%) compared with patients with single and
transient organ failure. Persistent organ failure is defined as lasting
greater than 24 hours regardless of intervention. Survival among patients
with organ failure at admission has also been shown to correlate with the
duration of organ failure. When organ failure is corrected within 48
hours, mortality is close to zero. When organ failure persists for more
than 48 hours, mortality is 36%. The Marshall Scoring System for organ
failure is commonly used by intensivists for patients admitted to an
intensive car unit. Data have not yet been generated using this system to
prognosticate mortality in acute pancreatitis. Studies are needed to
determine if this scoring system improves on the Ranson and APACHE
scoring systems.
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MODIFIED MULTIORGAN DYSFUNCTION SCORE
LABORATORY MARKERS
Because the degree of elevation of serum amylase and lipase does
not distinguish mild from severe pancreatitis, other factors have been
examined.
HEMATOCRIT
A high hematocrit on admission, or one that fails to decrease after
24 hours of rehydration is thought to be a sign of hemoconcentration due
to retroperitoneal fluid loss and thus a marker of severe disease. One
study showed that a hematocrit greater than 44% had a sensitivity of 72%
on admission and of 94% after 24 hours in detecting organ failure. The
negative predictive value at 24 hours was 96%. Although one study from
Germany found no correlation between admission hematocrit and organ
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failure, most investigators have found hematocrit to be important in the
management of patients with acute pancreatitis. An elevated hematocrit
(>44%) is a predictor for the development of necrosis. The hematocrit
should be observed at admission for prognostic purposes and followed
prospectively to assist in guiding the rate of intravenous hydration.
BLOOD UREA NITROGEN
Several prognostic scoring systems, including the Ranson criteria
and BISAP, incorporate blood urea nitrogen (BUN) for the prediction of
mortality in patients with acute pancreatitis. Hemoconcentration, as
described above, has been shown to be an accurate predictor of necrosis
and organ failure. Both BUN and the hematocrit or hemoglobin are
routine laboratory tests that may provide information on changes in
intravascular volume status. Either test may be used in monitoring the
early response to initial fluid resuscitation. Wu and colleagues recently
performed a large observational cohort study on data from 69 U.S.
hospitals and found that BUN may be superior to hemoglobin (not
hematocrit). For every 5 mg/dL increase in BUN during the first 24
hours, the age- and gender-adjusted odds ratio for mortality increased by
2.2. Of multiple routine laboratory tests examined, BUN yielded the
highest accuracy at 24 hours and 48 hours. Although further study is
needed, this paper suggests that following serial BUN measurements
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would be the most valuable single routine laboratory test for predicting
mortality in acute pancreatitis.
C-REACTIVE PROTEIN
CRP is an acute-phase reactant produced by the liver and is used
extensively in Europe as a marker of severe pancreatitis. CRP is
inexpensive to measure and readily available. The sensitivity for
detecting severe disease is 60% to 100% (using cutoffs of 100 to 210
mg/L, or 10 to 21 mg/dL) and the specificity is 75% to 100%.
INTERLEUKIN-6
IL-6 is an acute-phase-reactant cytokine that is produced by a
variety of cells and induces hepatic synthesis of CRP. Several studies
have shown that it is a reasonably good marker to differentiate mild from
severe disease, but the test is not readily available.
POLYMORPHONUCLEAR LEUKOCYTE ELASTASE
Polymorphonuclear leukocyte elastase rises very early (before
CRP) in acute pancreatitis. High levels have been reported to differentiate
severe from mild disease, but the test is not generally available.
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PHOSPHOLIPASE A2
PLA2 is involved in the release of prostaglandins from cell
membranes and degrades surfactant in the lung. It may play a role in the
pulmonary dysfunction associated with acute pancreatitis. Levels of
catalytic type II PLA2 have been reported to differentiate between mild
and severe disease within 24 hours of admission.
URINARY TRYPSINOGEN ACTIVATION PEPTIDE
Urinary TAP may serve as an early predictor of severity in patients
with acute pancreatitis. Unlike other markers of severity, such as CRP,
TAP is not a surrogate marker of inflammation. Normally trypsinogen is
cleaved to trypsin in the intestinal lumen by the enzyme enterokinase.
Premature intrapancreatic activation during acute pancreatitis results in
the release of TAP. The degree of pancreatic necrosis and systemic
inflammatory response or sepsis is directly related to TAP concentration.
Elevated urinary TAP (>30 nmol/L) correlates with disease severity. The
test can be applied within 12 hours of admission. The positive predictive
value of an elevated TAP is 80% and the negative predictive value
approaches 100%.
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PROCALCITONIN
This propeptide is another acute-phase reactant that has been
shown to differentiate mild from severe acute pancreatitis within the first
24 hours after symptom onset. A serum strip test has been developed that
has a sensitivity of 86% and a specificity of 95% in detecting organ
failure.
CHEST RADIOGRAPHY
A pleural effusion documented within 72 hours of admission by
chest radiography (or CT) correlates with severe disease.
COMPLICATIONS OF ACUTE PANCREATITIS
LOCAL COMPLICATIONS
? Pancreatic Necrosis
o Sterile
o Infected - abscess
? Pancreatic Pseudocyst
? Pancreatic Ascites
? Intraperitoneal hemorrhage
? Splenic vein Thrombosis
? Colonic stricture
58
? Obstructive jaundice
? Pancreatic pseudo aneurysm
SYSTEMIC COMPLICATIONS
? Pulmonary
o Pleural effusions
o Atelectasis
o Pneumonitis
o Mediastinal abscess
o ARDS ,  Respiratory failure
? Cardiovascular
o Shock- Hypovolaemic  & septic
o Pericardial effusion
? Hematologic
o DIC
? Gastrointestinal
o PUD
o Erosive gastritis
o  Erosion of Gastroduodenal vessels  or  inferior  and superior
arteries
o Portal vein thrombosis
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? Renal
o Oliguria
o Azotemia
o Renal artery/vein throbosis
o  ATN, Acute renal failure
?      Metabolic
o Hypocalcemia
o Hyperglycemia
o Encephalopathy
o Sudden blindness (Purtscher’s  retinopathy)
? Central nervous system
o Psychosis , Fat emboli
? Miscellaneous
o Septicemia
o Subcutaneous  fat
o Necrosis
? LONG TERM COMPLICATIONS
o Chronic Pancreatitis
o Abdominal Pain
o Steatorrhea
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o Exocrine insufficiency (pancreas has a 90% reserve for the
secretion of digestive enzymes)
o DM, i.e.Endocrine Insufficiency
o Pseudocyst
TREATMENT
The mainstay of treatment of acute pancreatitis is elimination of
inciting cause whereas treatment of chronic pancreatitis mainly involves
long term management of pain, pancreatic exocrine & endocrine
deficiency. The treatment needs to be tailored to each individual patient,
considering the techniques available in each Institution.
 General principle includes correcting any underlying predisposing
factors: Early ERCP in patients with gallstone pancreatitis who have
obstructive jaundice or biliary sepsis, Reversal of hypercalcemia,
Cessation of possible causative drug, The administration of insulin to the
poorly controlled diabetic with marked hypertriglyceridemia and lastly
the pancreatic inflammation itself.
Basic management of pancreatitis include
? Estimating severity
? Fluid & electrolyte management
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? The Control of Pain
? The Control of Nausea, Vomiting, Ileus
? Nutritional support
? Limiting progression
IMMEDIATE ASSESSMENT
Clinical assessment includes great care to assess respiratory,
cardiovascular and renal compromise. Body mass index: There is
considerable risk (> 30 kg/m2) or much greater risk > 40 kg/m2. Chest
X-ray: Is there a pleural effusion / pulmonary edema / ARDS present?
Contrast-enhanced CT: Is there more than 30% of the volume of the
pancreas malperfused. The use of various scoring systems to predict
severity of the disease and presence of organ failure.
Patients with predicted severe acute pancreatitis should be treated in
intensive care unit. In severe pancreatitis, ICU monitoring and support of
pulmonary, renal, circulatory, and hepatobiliary function may minimize
systemic sequelae.These patients need monitoring of vital signs and urine
output every few hours in the first 24 to 48 hours with further ongoing
monitoring for other complications that might arise .
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FLUID AND ELECTROLYTE MANAGEMENT:
Transudation of fluid from the intravascular space to the peritoneal
cavity is the principle cause of hypovolemia. “Cytokine Storm” causes
leaky capillaries and results in transudation. Other important cause are
vomiting, Insensible fluid loss due to tachypnoea and fever.Vomiting
usually leads to chloride and H+ loss leading to hypochloremic metabolic
alkalosis.
Fluid resuscitation is particularly important because patients with
necrotizing pancreatitis accumulate vast amounts of fluid in the injured
pancreatic bed.Inadequate hydration can lead to hypotension and acute
tubular necrosis.Fluid depletion damages pancreatic microcirculation and
results in pancreatic necrosis.Approximately 250 to 300 cc of intravenous
fluids per hour are typically required for 48 hours if the cardiac status
permits.
Adequate fluid replacement can be assessed by improvement in
vital signs and urine output and reduction in hematocrit over 24 hours,
particularly if it was high at the onset In some patients, a low urine output
may already reflect the development of ATN rather than persistent
volume depletion. Assessment of the patient’s volume status should be
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determined by heart rate, blood pressure, urine output and jugular venous
pressure.
Fluid management may be difficult when hypovolemia is
combined with ARDS.Fluid balance flow sheet is useful in such
cases.Pulse, BP & urine output are unreliable for fluid requirement in this
setting. Hematocrit may be useful in determining the fluid requirement.
Measurement of CVP will be accurate in determining fluid requirement
in this setting.
Potassium chloride should be added to the intravenous fluids to
achieve 100 mEq/day. Glucose levels greater than 13.9 mmol/L (250
mg/dL) necessitate insulin administration. A blood transfusion is
indicated if the patient’s hematocrit is less than 25%; values ranging from
30 to 35% are considered optimal for pancreatic parenchymal perfusion.
Hypoalbuminemia may be due to many patients are chronic
alcoholics Due to ongoing losses Albumin levels further depressed as
fluid losses are treated by albumin free colloids Treat it with albumin
infusion, if levels are very low.
Hypocalcemia is common, particularly during an acute attack, usually
attributable due to low serum albumin. No treatment required, if ionized
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calcium levels are normal. Aggressive calcium repletion required if
hypocalcemic features like tetany, carpopedal spasm occur.
Oxygen saturation needs to be assessed routinely and supplemental
oxygen administered to maintain arterial oxygen saturation of greater
than 95 percent. Blood gas analysis should be done if SaO2 is less than
95 percent or if clinical situation demands. Prophylaxis against DVT
should be considered in bedridden patients. Intermittent pneumatic
compression may be the preferred method because of the theoretical risk
of precipitating pancreatic hemorrhage with anticoagulation.
CONTROL OF PAIN
Pain of pancreatitis may be very severe and difficult to control.
Severe pain should be treated with meperidine 50 to 100 mg IM q 3 to 4 h
in patients with normal renal function. Morphine causes the sphincter of
Oddi to contract and should be avoided.
Nausea & vomiting can result in significant fluid & electrolyte
loss. Furthermore, retching can lead to UGI bleeding (mallory-Weiss
syndrome). Although institution of NG tube drainage has not been shown
to alter eventual outcome, to increase patient comfort NG tube drainage
can be done. Moreover instillation of NG tube dramatically reduces pain
in many patients of acute pancreatitis.
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NUTRITIONAL SUPPORT
Patients with severe pancreatitis may not be able to eat for
prolonged periods. Traditionally these patients have been given Total
Parenteral Nutrition. Recent studies show most patients of pancreatitis,
even those with severe pancreatitis, can tolerate small amounts of
enterally administered nutrients (Through NG or NJ tube).
SIRS, sepsis, organ failure, and ICU stay were globally improved
in the enterally-fed patients. The acute phase response and disease
severity scores CRP, APACHE II) were significantly improved following
enteral nutrition without any change in the CT scan scores. Enteral
feeding modulates the inflammatory and sepsis response in acute
pancreatitis and is clinically beneficial. There is also no doubt that
probiotics associated with enteral feeding may become an alternative
therapy replacing early antibiotic use to prevent infection in severe
pancreatitis.
To limit the progression of disease the patient should be advised to
stop smoking to stop smoking, to abstain from alcohol and to stop the
causative drugs.
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ANTIBIOTICS IN PANCREATITIS
 Infectious complications are still regarded as the primary cause of
mortality in severe pancreatitis. It is essential to identify the presence of
pancreatic necrosis and take measures to prevent infection. The current
recommendation is the use of a systemic antibiotic such as imipenem-
cilastatin 500 mg three times a day for 2 weeks in patients with
documented pancreatic necrosis. An acceptable strategy would be to
perform a CT scan with intravenous contrast at days 4–7 and begin
imipenem if necrosis is present. The use of early antibiotic treatment with
imipenem has been shown to decrease the need for surgical intervention.
If there is clinical evidence of infection, pancreatic necrosis should be
sampled by CT-guided fine needle aspiration (FNA). If infection is
confirmed, the tissue should be treated by surgical debridement, either via
open access or percutaneously.
Prophylaxis is indicated in only severe cases, not useful for mild
cases. Antibiotic prophylaxis significantly reduced sepsis by 21.1% and
mortality by 12.3% compared with no prophylaxis. There was also a non-
significant trend toward a decrease in local pancreatic infections.
Antibiotic prophylaxis decreases sepsis and mortality in patients with
acute necrotizing pancreatitis. All patients with acute necrotizing
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pancreatitis should receive prophylaxis with an antibiotic of proven
efficacy.
Few studies suggest prophylactic antibiotics have no benefit in the
outcome of an episode of acute pancreatitis. It favours emergence of
resistant strains at the site of pancreatic injury. Recently fungal strains
have been identified in the infected pancreatic necrosis cases.
ROLE OF SURGERY
It is to treat the underlying cause and for complications. Patients
with mild pancreatitis due to gall stones should undergo cholecystectomy
in the same admission.
Some have argued that a lack of stabilization or improvement with
full supportive intensive care therapy over 72 h should constitute an
indication for surgical intervention to establish intra-abdominal peritoneal
lavage, but no randomized study has validated this approach. When a
patient has clinical evidence of sepsis (usually > 7 days of onset)
unexplained by normal microbiology studies a CT scan should be
performed and FNA with immediate Gram stain and subsequent culture
of the fluid.
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Traditionally, an anterior open surgical approach either through a
transverse upper abdominal or a vertical incision has been routinely
advocated with exploration of the area of necrosis and infection, using
digital dissection or gentle instrumentation, to remove the dead tissue.
Postoperatively, lavage through strategically placed drains should
continue at a rate of 1–2 L/day and this may be required for 3 to 4 weeks
with a 30% chance of a repeat operation being necessary because of
recurrent sepsis.
Where venous bleeding and oozing of blood is particularly troublesome
packing of the upper abdomen with large cotton packs enclosed in
paraffin gauze or a similar non-adherent material may be necessary.
Alternatives to open surgery that are being actively investigated include
both anterior laparoscopic and retroperitoneal percutaneous approaches.
As one of the major purposes of surgical therapy in severe AP relates to
minimizing the risk of a further episode of pancreatitis it is logical and
wise to remove the gallbladder and check for any residual stones in the
CBD at the same operative procedure.
TREATMENT OF UNPROVEN VALUE
Peritoneal dialysis (designed to eliminate proinflammatory factors
released into abdomen) is of no benefit. Drugs reducing gastrointestinal
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or pancreatic secretions like atropine, antacids, somatostatin analogues
(octreotide, calcitonin) have not been beneficial. Inhibitors of proteolytic
enzyme (aprotinin, gabexate) are useless unless begun before the onset of
pancreatitis. Hypothermia, thoracic duct drainage, plasmapheresis are still
in experimental stage.
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INFLIXIMAB IN ACUTE PANCREATITIS
In acute edematous pancreatitis and in severe necrotizing
pancreatitis, the drug significantly decreased serum amylase activity and
the histopathologic score. In severe necrotizing pancreatitis, it
ameliorated both parenchymal and fatty tissue necrosis of the pancreas. It
also alleviated alveolar edema and ARDS-like pulmonary complications,
but this difference was not significant.
RESVERATROL IN ACUTE PANCREATITIS
To evaluate the protective and antioxidative effect of resveratrol, a
stilbene derivative, in acute pancreatitis induced by tert-butyl
hydroperoxide injection. Changes in pancreas were much less
pronounced in the rats which received resveratrol for 8 days prior to tert-
butyl hydroperoxide injection.In this way it seems that stilbene
derivatives may prevent pancreatic cells from undergoing structural
changes during acute pancreatitis experimentally induced in rats
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AIMS AND OBJECTIVES OF THE STUDY
? To compare CT severity scoring system with the  multifactorial
scoring systems: Glasgow/IMRIE  and BISAP  in predicting severity,
pancreatic necrosis  and mortality in a prospective cohort of patients
with acute pancreatitis which is analysed retrospectively
? To find out which among the three studies has strong association in
predicting the complications?
? To stratify the patients based on the predicted severity and provide
intensive care treatment earlier in the course of disease and thereby
decrease morbidity and mortality.
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MATERIALS AND METHODS
SETTING:
Department of general surgery, Stanley medical college and
hospital, Chennai. The study was done after obtaining institutional ethical
committee approval.
DURATION:
Nov 2012 to Nov 2013
STUDY DESIGN:
 Observational comparative analytical study
INCLUSION CRITERIA:
? Age >15 years including both sexes.
? Patients with clinical features of pancreatitis  and S. amylase/ S. lipase
equal to or more than 3 times the upper limit of normal or
? Radiological evidence of presence of acute pancreatitis.
EXCLUSION CRITERIA:
? Patient less than 15 yrs in age
? Proven cases of chronic pancreatitis.
? Hereditary pancreatitis.
? Patients with comorbidities like COPD, renal impairment,
immunosuppressive state, etc.
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METHODOLOGY
Demographic, clinical, and laboratory data of all consecutive
patients with a primary diagnosis of ACUTE PANCREATITIS  during a
one year period is prospectively  collected for this study. A retrospective
analysis of the abdominal CT data is performed. CT severity index as
well as two clinical scoring systems:  Glasgow criteria / IMRIE’S
prognostic criteria and Bedside Index for Severity in Acute pancreatitis
(BISAP) were comparatively evaluated with regard to their ability to
predict the severity of acute pancreatitis on admission (within 48 h of
hospitalization).
 Clinically severe Acute was defined as one or more of the
following: mortality, temporary/ persistent organ failure and/or the
presence of local pancreatic complications that require intervention. All
CT scans were reviewed in consensus by two radiologists, each blinded
to patient outcome. The accuracy of each imaging and clinical scoring
system for predicting the severity of AP was assessed using appropriate
statistical tools.
First 50 patients attending the surgical emergency ward with
clinical features of Acute Pancreatitis are evaluated clinically and
subjected to laboratory and radiological investigations as per the designed
proforma. (annexure 1). Data pertinent to the scoring systems will be
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recorded within 24hr of admission to the hospital. Once diagnosis is
established the patient disease severity will be assessed by following the
scoring systems
? CT SEVERITY INDEX
? MODIFIED GLASGOW
? BISAP
The etiology of the disease has been analysed and divided into
alcoholic, biliary, drug induced, hypertryglyceridimia and idiopathic.
Biliary pancreatitis has been confirmed only after visualization of stone
in gall bladder or biliary tract with the help of an ultrasound or computed
tomography.
The outcome of the patient is recorded in the form of survivor or
non- survivor. Complications that developed in the course of disease
while the patient was in the hospital have been recorded. All patients
have been followed up until discharge or death.
OBSERVATION AND RESULTS
The study was conducted in general surgery department, Stanley
medical college for a period of one year. Totally 50 patients with features
of acute pancreatitis were enrolled in the study after obtaining proper
informed consent.
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TABLE 5: AGE DISTRIBUTION
AGE IN YEARS NO. OF PATIENTS PERCENTAGE
21-30 13 26%
31-40 15 30%
41-50 12 24%
51-60 9 18%
61 and Above 1 2%
TOTAL 50 100%
Among the 50 cases nearly 80% are between the age group of 21 to 50
years and only 2% of the people above 60 years had the disease.
GRAPH 1: BISAP VS AGE
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The age cut off in BISAP score is 60 years and for patients above
the age of sixty, the severity is predicted to be more and hence one point
is added. In the above study only two patients were above 60 and the
graph shows that both the patients had maximum BISAP score suggestive
of severe pancreatitis.
GRAPH 2: GLASGOW VS AGE
In Glasgow the cut- off age is 55 and arbitrarily patients more than
55 years have more severe pancreatitis than patients less than 55 yrs but
the above graph in my study showed that among the 5 patients more than
55 yrs two had severe and three had mild pancreatitis according to
Glasgow score
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TABLE 6: SEX DISTRIBUTION
AGE IN
YRS
NO. OF
MALES
NO. OF
FEMALES
PERCENTAGE
males Females
21 - 30 12 1 24% 2%
31 – 40 10 5 20% 10%
41 – 50 10 2 20% 4%
51 – 60 8 1 16% 2%
>60 0 1 0 2%
TOTAL 40 10 80% 20%
80% of the cases are male and among males only 16% are above 50 years
of age.  Among females which form the remaining 20%  only 4% are
above 50 yrs of age.
MALES
80%
FEMALES
20%
SEX DISTRIBUTION
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GRAPH 3: SEX DISTRIBUTION IN GLASGOW SCORE
The above graph compares the variation of Glasgow score between
both sexes and it shows males sex is predominantly affected by mild
pancreatitis (35 male patients have score equal to or below three) and
similarly females are also mostly experiencing mild pancreatitis (only
one female out of ten had a score more than three).
SEX DISTRIBUTION IN BISAP SCORE
In the below graph, we compare variations of bisap score with sex.
Nearly 45% of males and 40% of females are having a score of 3 or more
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as against Glasgow which shows only 12.5%  of males and 10%of
females with score more than three.
GRAPH 4: BISAP SCORE VARIATION IN BOTH SEX
TABLE 7: CLINICAL FEATURES
Symptoms No. of patients Percentage (%)
Pain abdomen 43 86
Fever 30 60
Vomiting 17 34
Jaundice 10 20
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At the time of admission nearly 85% had abdominal pain with or without
other features as their presenting complaint. Remaining 14% had either
vomiting, jaundice or fever as their complaints.
TABLE 8:  ETIOLOGIES
Etiology No. of patients Percentage (%)
Alcohol 32 64
Gall stone disease 8 16
Drug induced 1 2
Hypertriglyceridemia 1 2
Trauma Nil 0
Idiopathic 8 16
PAIN
43
FEVER
30
VOMITING
17
JAUNDICE
10
NO. OF PATIENTS WITH SYMPTOMS
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Among  the 50 cases nearly 64% are predicted to have alcohol as their
etiology with gall stone disease forming 16%  and pancreatitis due
idiopathic causes forming another 16%.
TABLE 9: NO. OF PATIENTS WITH COMPLICATIONS
Complication No. of patients Percentage (%)
Acute renal failure 3 18.7
Acute respiratory distress
syndrome
1 6.25
Pancreatic necrosis 6 37.5
Multi-organ dysfunction
syndrome
4 25
Septicemia 2 12.5
Pseudo cyst 4 25
Hypocalcemia 1 6.25
ALCOHOL
64%
GALL STONE
16%
IDIOPATHIC
16%
DRUG
2%
HYPERTRIGLYCERID
ES
2% ETIOLOGY
82
Out of 16 patients who had either organ failure or local
complications or both, acute renal failure was seen in 18%  and MODS
was seen in 25% of patients. Local complications like pancreatic necrosis
were seen in 37.5% cases and pancreatic psuedocyst in 25% cases.
TABLE 10:  COMPARING SCORING SYSTEM WITH ORGAN
FAILURE
SCORING SYSTEM NO.
OF
PTS
ORGAN
FAILURE
PANCREATIC
COMPLICATIONS
MORTALITY
BISAP
<2 27 NIL NIL NIL
? 3 23 9 10 4
GLASGOW
<2 40 3 5 2
?3 10 6 5 2
CTSI
<3 44 6 4 1
?4 6 3 6 3
Out of 50 cases 16 developed organ failure or local pancreatic
complications or both  with  4 cases of mortality among them.
BISAP score was able to predict both organ failure and local
complications when the cut off score is 2 (that is all patients with score 3
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or more had either organ failure or local complications). All the four
cases of mortality had score 3 or more. In other words severity and
mortality prediction when the cut off value is 2 is 100%.
Glasgow score was able to predict organ failure in 66% of cases
when score was at or above 3 and only 50% of local pancreatic
complications and 50% of mortality.
In CTSI when an arbitrary cut off value of 4 (that is patients with
necrosis) is set only three patients above 4 developed organ failure and
three patients had mortality. Hence when necrosis is indicated in CTSI
organ failure is only 33% and mortality is 50%.
GRAPH 5: GLASGOW VS COMPLICATIONS
In this graph it can be seen that the number of people with
Glasgow below two who have developed complications (either organ
failure or local complications) is significant. This means nearly 37% of
patient who were predicted to have mild pancreatitis developed
complications.
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GRAPH 6: BISAP VS COMPLICATIONS
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In the above graph, it is clearly indicated that no complications
were seen when score is less than 2 and with score above 3 or more the
complication pick up rate is 100%.  It can also be seen that out of 23
patients who were predicted to have severe disease only 16 (that is 69%)
developed complication.
GRAPH 7: CTSI VS COMPLICATION
In this graph it is seen that among 44 patients with score less than
four (that is only pancreatic inflammation) 6 have developed either organ
failure and hence 13% of complications has been missed in this
complications.
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TEST TO INDICATE THE CORRELATION OF THE RESULTS
WITH THE PRESENCE OF COMPLICATIONS
H0: there is no correlation between the test results and the presence of
complication
H1: There exist a significant correlation between the results of the test
and the complication
complications_var
iable
glasglow_3
Pearson
Correlation .514
**
Sig. (2-tailed) .000
N 50
BISAP_3
Pearson
Correlation .826
**
Sig. (2-tailed) .000
N 50
CTSI_4
Pearson
Correlation .514
**
Sig. (2-tailed) .000
N 50
Interpretation
Since the sig.(2 tail) p value is less than 0.05, there is a correlation
between the test results and the presence of complication. The correlation
analysis of the presence of complication with the three scoring methods
reveals that the BISAP has high correlation of 82.6% than other two tests.
Thus presence of complication has 82.6% effect on given positive results
in the test. Glasgow and CTSI has 51.4% correlation.
87
TEST TO DETERMINE THE STRENGTH OF THE METHOD ON
DETERMINING THE COMPLICATION (CRAMER’S V TEST)
BISAP
Crosstab
complications_va
riable
Total
.00 1.00
BISAP_3
.00
Count 33 4 37
% within
complications_variable 100.0% 23.5% 74.0%
1.00
Count 0 13 13
% within
complications_variable 0.0% 76.5% 26.0%
Total
Count 33 17 50
% within
complications_variable 100.0% 100.0%
100.0
%
H0: There is no association with the test results and the complication
H1: There is a significant association with the test results and the
complication
Symmetric Measures
Value Approx.
Sig.
Nominal by
Nominal
Phi .826 .000
Cramer's
V .826 .000
N of Valid Cases 50
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Interpretation
The first table explains that in 23.5%  cases the BISAP is negative when
the subject actually has the complication. The Cramer’s V test shows that
there is a significant association of the test result to the presence of
complication and the strength of association is 0.826 (i.e.) very high
association.
GLASGOW
Crosstab
complications_va
riable
Total
.00 1.00
glasglow_3
.00
Count 33 11 44
% within
complications_variable 100.0% 64.7% 88.0%
1.00
Count 0 6 6
% within
complications_variable 0.0% 35.3% 12.0%
Total
Count 33 17 50
% within
complications_variable 100.0% 100.0%
100.0
%
H0: There is no association with the test results and the complication
H1: There is a significant association with the test results and the
complication
Symmetric Measures
Value Approx.
Sig.
Nominal by
Nominal
Phi .514 .000
Cramer's V .514 .000
N of Valid Cases 50
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Interpretation
The first table indicates that there is a 64.7% that the test would be
normal when the subject is actually suffering from a complication. The
strength of association is 0.514 which is moderate association.
CTSI
Crosstab
complications_va
riable
Total
.00 1.00
CTSI_
4
.00
Count 33 11 44
% within
complications_variable 100.0% 64.7% 88.0%
1.00
Count 0 6 6
% within
complications_variable 0.0% 35.3% 12.0%
Total
Count 33 17 50
% within
complications_variable 100.0% 100.0%
100.0
%
H0: There is no association with the test results and the complication
H1: There is a significant association with the test results and the
complication
Symmetric Measures
Value Approx.
Sig.
Nominal by
Nominal
Phi .514 .000
Cramer's V .514 .000
N of Valid Cases 50
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Interpretation
The first table indicates that there is a 64.7% that the CTSI would be
normal when the subject is actually suffering from a complication. The
strength of association is 0.514 which is moderate association.
Note on Cramer’s V test
0-0.30? Weak association
0.31-0.70? Medium or moderate association
0.71- 1.0? strong association
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SCORING SYSTEM
SURGICAL INTERVENTION
Incorrectly predicted
Correctly predicted
MANAGEMENT
All except four patients managed conservatively.
Three patients underwent emergency laparotomy. Two patient had
acute severe necrotizing pancreatitis which was initially managed
conservatively later they developed severe pancreatitis with intra-
abdominal abscess, that required laparotomy and drainage procedure.
GRAPH 8 : PATIENTS REQUIRING SURGERY AS PER BISAP
AND GLASGOW
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One patient with severe disease have developed pseudocyst,
underwent laparotomy and internal drainage.
Another patient who had severe pancreatitis underwent
necrosectomy initially& has developed pancreatic fistula later, which was
managed by pancreatic duct stenting. The BISAP score has predicted all
the four patients correctly as severe pancreatitis, whereas GLASGOW
score predicted only two of the cases as severe pancreatitis.
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DISCUSSION
Acute pancreatitis is a disease with a large and varies spectrum of
presentation. In acute pancreatitis with chances of high mortality, early
hospitalization is needed to identify those who require aggressive
interventions to prevent the severe attack of AP.
 In this study, the three different scoring systems (BISAP ,
GLASGOW and CTSI) were compared and analyzed to assess the
severity in patients with acute pancreatitis. An attempt also made to
compare this study with previous similar studies done by others.
Acute pancreatitis found to be 4 times more common in males than
females in this study because alcohol consumption was the predominant
cause which was more common in males. This result matches with
previous study results,  Vikesh K.  Singh et  al38 (6:1), Papachristou et al1
(5.1:1).
 Patients less than 15 years of age were excluded in this study,
because the normal values of heart rate and respiratory rate are higher at
younger age group. So, if these patients had been included in this study,
they could have got higher scores incorrectly and could have predicted
incorrectly as at risk for developing severe pancreatitis, even with mild
disease.
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Age is considered as a significant contributory factor in predicting
the outcome of severe acute pancreatitis. In my study BISAP scoring with
age cut off as 60, all patients above this age had severe pancreatitis but in
GLASGOW only 40% above the cut off age of 55 had  severe
pancreatitis and henceforth BISAP has better prediction than GLASGOW
in old age patients. This variable cannot be applied to CTSI.
The most common etiological factor in this study was alcohol
(64%) and matches with Bidarkundi et al43(46.67%), but didn’t correlate
with results of Vikesh K. Singh et al38 (21.4%), Papachristou et al1 (14%)
wherein gall stone disease found to be the most common cause, 27% &
36% respectively.
The most common presentation was predominantly abdominal pain
(86%), followed by fever (60%), vomiting (34%) & other manifestations.
In this study, 34 patients were diagnosed to have mild acute
pancreatitis and 16 patients found to have severe acute pancreatitis. All
the 16 patients were correctly predicted by BISAP Score. The severity
was assessed by correlating the scores with three factors: organ failure,
necrosis and mortality.
The other two scoring systems namely GLASGOW and CTSI were
able to pick up only 50% of complication rates.
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On  keeping  the  cut  of  value  for  BISAP  as  3,  GLASGOW  as  3
AND CTSI as 4 and analyzing using PEARSON CORRELATION it was
found BISAP had 82.6% correlation compared to GLASGOW and CTSI
which only had 51.4% correlation. If BISAP score predicts the disease to
be severe then there is 82% positivity that the patient will have acute
severe pancreatitis.
In CRAMER V test the strength of association was found to be
0.826 for BISAP score which is very high for predicting complications.
In other words only 23.6% of people with negative BISAP score will
have complication. The strength of association for Glasgow and CTSI
was 0.514 which is moderate association and there is 64.7% chance of
negative score even the patient has severe complications. In this study,
4% underwent surgical intervention which comparable with Sarath et al.
In this study, 4 patients with severe acute pancreatitis were expired.
All four deaths were correctly predicted by BISAP score. Three patients
were expired due to MODS and one patient expired due to septicemia
In this study, 37.5% developed acute pancreatic necrosis, 25%
developed MODS, 25% developed psuedocyst and 18% developed acute
renal failure. All these complications were correctly predicted in patients
with BISAP ? 3 and hence concluded that these are the patients in high
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risk group, who requires intensive monitoring and probably early
intervention if necessary.
BISAP score was found to have better correlation, high strength of
association and diagnostic accuracy with less negative value, compared to
GLASGOW and CTSI in predicting the severity of acute pancreatitis.
Hence, BISAP score found to predict more number of patients, likelihood
of progressing to severe disease. Larven et al stated in their study that, a
prognostic scoring assay should preferably have high positive and
negative predictive values or high negative predictive value to assess the
severity of acute pancreatitis. Hence, BISAP is considered as better score
in assessing the severity than GLASGOW and  CTSI Score.
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LIMITATIONS OF THIS STUDY ARE:
• Small number of patients in this study.
• The etiology in this study were found to be different from
worldwide accepted one, hence might not be correct to compare
with other studies.
• The GCS score used to assess the mental status of the patient got
admitted were subject to interobserver variation.
• Various factors associated with the disease like cholangitis, alcohol
withdrawal may interfere with the assessment of physiological
scores, which may leads to difference in the results.
• Recently, it has been suggested that severe acute pancreatitis may
have variable disease progression; therefore the lack of
predictability might be associated with this disease variability.
• Variation in timing of presentation of patients to the hospital after
onset of symptoms may interfere with assessment of the scoring
systems.
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CONCLUSION AND SUMMARY
• From this study, Alcohol (64%) was found to be the most common
etiological factor for acute pancreatitis.
• Males were most commonly affected than female with a ratio of 4:1.
• The most common age groups of patients affected were in 2ND to 4th
decade of life.
• The overall mortality in patients with severe acute pancreatitis was
8%.
• All the three scores were significant in predicting severity and
complications but BISAP had the highest strength of association
among the three to correctly predict severity and mortality.
• From this study, we conclude that the BISAP score could be a simple
and better clinical scoring system for the evaluation of disease
severity in acute pancreatitis than GLASGOW and CT severity index.
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ANNEXURE 2: PROFORMA
 “Comparative Evaluation Of Radiologic And Clinical Scoring
Systems In Early Prediction Of Severity Of Acute Pancreatitis”
Investigator: Dr.S. VIJAY RAJ, PG – MS (Gen Surg)
• Name : sl. No:
• Age /sex:
• Address with contact number:
• Ip no:
• Date of admission:
• Date of surgery:
HISTORY OF PRESENTING ILLNESS:
Pain :  duration , location , character
Vomiting:  onset :     duration:
Nausea
Fever
           Jaundice
Any other relevant h/o
PAST HISTORY:
WHETHER A KNOWN CASE OF
DM/HYPERTENSION/ASTHMA/TB/EPILEPSY/CARDIAC ILLNESS
H/O SIMILAR EPISODES IN THE PAST, IF ANY:
CLINICAL EXAMINATION:
GENERAL EXAMINATION:  TEMP:          P.R:       B.P:       R.R
SYSTEMIC EXAMINATION:
CVS
RS
PER ABDOMEN:
CLINICAL DIAGNOSIS:
Investigations:
HEMAT LFT
HB T.BIL
PCV D.BIL
RBC AST
TC ALT
DC ALP
PLT T.PROTEIN
ESR S.ALB
RBS
S.AMYLASE
S. LIPASE
P.T - T/C
INR
B.UREA LDH
S.CREAT S.CALCIUM
S.Na+ ABG
S.K+ BUN
S.Cl- BL.GROUP
S.HCO3-
CHEST X RAY :
ABD X RAY:
USG ABD:
PLAIN CT / CECT ABD
PATIENT CLINICAL COURSE:
OUTCOME OF TREATMENT:
MODIFIED GLASGOW SCORE:
Pa02 <60mm
Hg
1
>60mm
Hg
0
AGE >55 yrs 1
<55 yrs 0
NEUTROPHILLIA >15000  1
S. CALCIUM <8 mg/dl 1
>=8 mg/dl 0
S. UREA NITROGEN >45 mg/dl 1
<= 45
mg/dl
0
S. LDH > 600 U/l 1
< = 600
U/l
0
S. ALBUMIN <3.2 g/dl 1
>3.2g/dl 0
BLOOD SUGAR >180
mg/dl
1
<= 180
mg/dl
0
BISAP
? Blood urea nitrogen (BUN) >25 mg / dl.
? Impaired mental status (GCS < 15).
? SIRS.
? Age >60 years.
? Pleural effusion.
SIRS is defined by presence of two or more of the following criteria:
? Pulse rate > 90/min.
? Respiratory rate > 20/min or PaCO 2 < 32 mm Hg.
? Temperature >100.4 F or < 96.8 F / < 36 or > 38 ° C.
? WBC count >12,000 or < 4,000 cells/mm3, or presence of more than
10% immature blasts.
Modified Glasgow score > 3  indicates severity
BISAP > 3 indicates severity
 CT SEVERITY INDEX WITH BALTHAZAR GRADE:
Prognostic Indicator Points Grade
Pancreatic inflammation
Normal pancreas
Focal or diffuse enlargement of the pancreas
Intrinsic pancreatic abnormalities with inflammatory
changes in peripancreatic fat
Single, ill-defined fluid collection or phlegmon
Two or more poorly defined collections or presence of
gas in or adjacent to the pancreas
Pancreatic necrosis
None
? 30%
> 30–50%
> 50%
0
1
2
3
4
0
2
4
6
A
B
C
D
E
A COMPARATIVE EVALUATION OF RADIOLOGIC AND
CLINICAL SCORING SYSTEMS IN EARLY PREDICTION OF
SEVERITY IN ACUTE PANCREATITIS
Investigator: Dr.Vijay Raj, PG – MS (Gen Surg).
___________________________________________________________
Patient Information Module
You are being invited to be a subject in this study.
Before you participate in this study, I am giving you the following
details about this trial, which includes the aims, methodology, intervention,
possible side effects, if any and outcomes:
All patients diagnosed with pancreatitis on clinical grounds or
imaging will be included in this study. A detailed clinical history will be
taken following a standardized proforma. A detailed clinical examination
will be made and relevant investigations, basic and special investigations
will be done at the time of admission. CT scan will be done at the time of
admission. Efficacy between clinical and radiological scoring systems in
predicting severity of pancreatitis will be analysed. The results arising
from this study will be analyzed and used for academic purposes. You will
be given clear instructions at every step and you are free to ask/ clarify any
doubts. Your identity will remain confidential. You are free to withdraw
from this trial at any point of time, without any prior notice &/ or without
any medical or legal implications.
I request you to volunteer for this study.
Thanking You,
Investigator’s Sign Patient’s Sign
(Dr.S.VIJAY RAJ)          Name:

A COMPARATIVE EVALUATION OF RADIOLOGIC AND
CLINICAL SCORING SYSTEMS IN EARLY PREDICTION OF
SEVERITY IN ACUTE PANCREATITIS
Investigator: Dr. S.VIJAY RAJ, PG – MS (Gen Surg)
___________________________________________________________
Informed Consent
Name: Age/ Sex:
IP:
I herewith declare that I have been explained in a language fully
understood by me regarding the purpose of this study, methodology,
proposed intervention, plausible side effects, if any and sequelae.
I have been given an opportunity to discuss my doubts and I have received
the appropriate explanation.
I understand that my participation in this study is completely voluntary and
that I am free to withdraw from this study at anytime without any prior
notice &/ or without having my medical or legal rights affected.
I permit the author and the research team full access to all my records at
any point, even if I have withdrawn from the study. However my identity
will not be revealed to any third party or publication.
I herewith permit the author and the research team to use the results and
conclusions arising from this study for any academic purpose, including
but not limited to dissertation/ thesis or publication or presentation in any
level.
Therefore, in my full conscience, I give consent to be included in the study
and to undergo any investigation or any intervention therein.
Patient’s Sign    Investigator’s Sign
    (Dr.VIJAY RAJ)
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N
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ET
IO
LO
G
Y
G
L
A
SG
O
W
BI
SA
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M
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M
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IC
A
TI
O
N
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M
A
N
A
G
EM
EN
T
1 RAJENDRAN 35399 44 MALE * * NIL NIL ALCOHOL 1 2 1 ALIVE CONSERVATIVE
2 ISRATH 34332 40 FEMALE * NIL NIL NIL GALL STONE 2 2 1 ALIVE CONSERVATIVE
3 MUTHU 34612 52 MALE * NIL * NIL ALCOHOL 5 4 3 ALIVE ARF CONSERVATIVE
4 GNANVEL 30077 39 MALE * NIL NIL NIL ALCOHOL 0 2 2 ALIVE CONSERVATIVE
5 NAGAPPAN 16628 26 MALE * NIL * * IDIOPATHIC 1 2 1 ALIVE CONSERVATIVE
6 MIJAZ MOHD. 26301 43 MALE * NIL NIL NIL ALCOHOL 2 4 2 ALIVE ARDS CONSERVATIVE
7 SHANTHA 66982 64 FEMALE * NIL NIL NIL GALL STONE 8 5 8 DEAD PANC. NECROSIS WITH MODS CONSERVATIVE
8 ARUN 18441 52 MALE * NIL * NIL IDIOPATHIC 0 3 2 ALIVE CONSERVATIVE
9 VINOTH 23987 28 MALE * NIL NIL * ALCOHOL 2 2 1 ALIVE CONSERVATIVE
10 CHINNAPAIYAN 6918 48 MALE * * NIL NIL ALCOHOL 1 4 6 DEAD PANC. NECROSIS CONSERVATIVE
11 JANARDHANAN 21635 26 MALE * NIL * * ALCOHOL 1 3 2 ALIVE CONSERVATIVE
12 DAMODARAN 39206 31 MALE * NIL * NIL GALL STONE 3 3 3 ALIVE PSEUDOCYST SURGERY
13 ALBERT 22530 30 MALE * * NIL * ALCOHOL 1 2 1 ALIVE CONSERVATIVE
14 ABDUL QADER 7989 30 MALE * NIL * * ALCOHOL 0 3 1 ALIVE CONSERVATIVE
15 SUBRAMANI 6923 33 MALE * NIL * NIL ALCOHOL 1 2 1 ALIVE CONSERVATIVE
16 VENKATESAN 17439 20 MALE * * * * GALL STONE 6 4 3 ALIVE ARF CONSERVATIVE
17 BISHNU 320761 45 MALE * * * NIL ALCOHOL 1 3 3 ALIVE PSEUDOCYST SURGERY
18 FATHIMA 26665 33 FEMALE * * * NIL IDIOPATHIC 2 2 2 ALIVE CONSERVATIVE
19 SENTAMIL SELVI 37807 48 FEMALE * NIL * NIL GALL STONE 3 4 6 AMA PANC. NECROSIS CONSERVATIVE
20 THILAI NATHAN 36395 34 MALE NIL NIL * NIL ALCOHOL 0 2 1 ALIVE CONSERVATIVE
21 RAJA 37386 54 MALE * NIL * NIL ALCOHOL 1 2 1 ALIVE CONSERVATIVE
22 VIJAYAKUMAR 39214 36 MALE * NIL * NIL ALCOHOL 0 1 1 ALIVE CONSERVATIVE
23 SENTHILVEL 39206 55 MALE * NIL * NIL ALCOHOL 4 4 6 ALIVE PANC. NECROSIS SURGERY
24 SURYA 39216 44 MALE * * * * ALCOHOL 6 4 8 DEAD PANC. NECROSIS CONSERVATIVE
25 NALLAKANNU 56890 29 MALE * NIL NIL NIL IDIOPATHIC 0 2 1 ALIVE CONSERVATIVE
26 THANGARASU 37469 52 MALE NIL NIL NIL NIL ALCOHOL 1 2 1 ALIVE CONSERVATIVE
27 SHANTHI 37419 60 FEMALE * NIL * * GALL STONE 3 5 3 ALIVE MODS - SEPSIS CONSERVATIVE
28 GURU 49947 40 MALE * NIL NIL NIL ALCOHOL 1 3 3 ALIVE PSEUDOCYST CONSERVATIVE
29 DAS 20029 28 MALE NIL NIL NIL NIL ALCOHOL 1 2 1 ALIVE CONSERVATIVE
30 GEORGE 38435 59 MALE * NIL * NIL ALCOHOL 1 2 1 ALIVE CONSERVATIVE
31 ANGAMMA 42262 27 FEMALE * NIL NIL NIL HYPER TGL 3 3 2 ALIVE HYPOCALCEMIA CONSERVATIVE
32 VADIVEL 40677 38 MALE * * NIL NIL IDIOPATHIC 0 2 1 ALIVE CONSERVATIVE
33 PANDIYAN 42845 33 MALE NIL NIL * * ALCOHOL 1 2 1 ALIVE CONSERVATIVE
34 MAHARANI 64784 37 FEMALE * * * NIL ALCOHOL 0 2 1 ALIVE CONSERVATIVE
35 KAMARAJ 42947 31 MALE * * * NIL ALCOHOL 0 1 1 ALIVE CONSERVATIVE
36 PERIYASAMY 34459 42 MALE * NIL * * ALCOHOL 2 4 6 ALIVE PANC. NECROSIS CONSERVATIVE
37 BHARATHI 34520 46 FEMALE NIL * NIL NIL GALL STONE 2 3 2 ALIVE CONSERVATIVE
38 KUPPAN 34781 48 MALE * * NIL NIL ALCOHOL 0 2 1 ALIVE CONSERVATIVE
39 FAROOQ 33291 41 MALE * * * NIL ALCOHOL 2 3 1 ALIVE CONSERVATIVE
40 RAVI 33413 49 MALE * NIL * NIL IDIOPATHIC 1 2 1 AMA CONSERVATIVE
41 RAJAN 30601 51 MALE * NIL * NIL IDIOPATHIC 1 4 3 ALIVE PSEUDOCYST SURGERY
42 SINGARAM 33744 29 MALE * * NIL NIL ALCOHOL 2 1 1 ALIVE CONSERVATIVE
43 JEEVA 12075 56 MALE NIL NIL * NIL ALCOHOL 2 2 1 ALIVE CONSERVATIVE
44 HARI 32520 33 MALE * NIL NIL NIL DRUG 5 4 3 AMA ARF CONSERVATIVE
45 DURAI 28928 49 MALE * NIL * NIL ALCOHOL 0 4 1 DEAD SEPSIS CONSERVATIVE
46 JOSEPH 30619 27 MALE * NIL * NIL IDIOPATHIC 1 0 1 ALIVE CONSERVATIVE
47 RADHA 88937 39 FEMALE NIL * NIL NIL GALL STONE 0 2 1 ALIVE CONSERVATIVE
48 SAMIKANNU 59188 28 MALE * * * NIL ALCOHOL 1 3 2 ALIVE CONSERVATIVE
49 KUTTIYAMMAL 19136 36 FEMALE * * NIL NIL ALCOHOL 2 2 1 ALIVE CONSERVATIVE
50 BALU 26621 28 MALE * NIL * NIL ALCOHOL 0 2 2 ALIVE CONSERVATIVE
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